Table 3.
Cox regression model for IRIS development
| Characteristics | IRIS-KS (n = 35) | Non-IRIS-KS (n = 54) | Unadjusted HR (95% CI) | p value | Adjusted HR (95% CI) | p value |
|---|---|---|---|---|---|---|
| IRIS | ||||||
| HIV-RNA at follow-upa | ||||||
| <100 copies/mm3 | 25 (81) | 48 (96) | 1.00 | |||
| >100 copies/mm3 | 6 (19) | 2 (4) | 5.76 (0.92–61) | 0.04 | 2.26 (0.58–8.89) | 0.239 |
| Pulmonary involvement | ||||||
| No | 14 (40) | 45 (83) | 1.00 | |||
| Yes | 21 (60) | 9 (17) | 7.5 (2.53–22.79) | <0.0001 | 3.20 (1.12-9.12) | 0.02 |
| Platelets at follow-upb | ||||||
| >100,000/mm3 | 20 (65) | 48 (96) | 1.00 | |||
| <100,000/mm3 | 11 (35) | 2 (4) | 13.2 (2.46–128.61) | 0.003 | 2.79 (0.92–8.43) | 0.06 |
aDetectable viral load >1000 copies/mm3 at 12-week follow up. Viral load was documented in 81 patients
bPlatelets <100,000/mm3 at 12-weeks follow-up. 81 patients had platelets count at follow-up